FLEROXACIN IN UROGENITAL INFECTIONS

Fleroxacin, a novel new-quinolone, was administered to 17 patients and the results described below were obtained. 1. Of 11 patients with complicated urinary tract infection (UTI), excellent results were observed in 2, moderate in 4 and poor in 5. The overall clinical efficacy rate was 54.5%. 2. In b...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 38; no. Supplement2; pp. 539 - 545
Main Authors MATSUMOTO, TETSURO, HIRATA, HIROSHI, KOMATSU, KIYOSHI, KOIKAWA, YASUHIRO, TANAKA, MASATOSHI, KUMAZAWA, JOICHI, OGATA, NOBUO, HARA, SANSHIN, MIYAZAKI, NORIYOSHI
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1990
公益社団法人 日本化学療法学会
Subjects
Fleroxacin
複雑性尿路感染症
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.38.Supplement2_539

Cover

Abstract Fleroxacin, a novel new-quinolone, was administered to 17 patients and the results described below were obtained. 1. Of 11 patients with complicated urinary tract infection (UTI), excellent results were observed in 2, moderate in 4 and poor in 5. The overall clinical efficacy rate was 54.5%. 2. In bacteriological response, 9 of 14 strains (64.3%) were diminished. 3. As classified by dose and timing, clinical efficacy rates were 40% in the 100mg once daily group, 66.7% in the 200mg once daily group and 66.7% in the 200mg twice daily group. 4. Clinical efficacy in one case of acute uncomplicated cystitis was excellent. 5. Side effects were stomach discomfort and diarrhea in one case, and abnormal elevation of GOT, GPT and ALP in another.
AbstractList Fleroxacin, a novel new-quinolone, was administered to 17 patients and the results described below were obtained.1. Of 11 patients with complicated urinary tract infection (UTI), excellent results were observed in 2, moderate in 4 and poor in 5. The overall clinical efficacy rate was 54.5%.2. In bacteriological response, 9 of 14 strains (64.3%) were diminished.3. As classified by dose and timing, clinical efficacy rates were 40% in the 100mg once daily group, 66.7% in the 200mg once daily group and 66.7% in the 200mg twice daily group.4. Clinical efficacy in one case of acute uncomplicated cystitis was excellent.5. Side effects were stomach discomfort and diarrhea in one case, and abnormal elevation of GOT, GPT and ALP in another. Fleroxacinを複雑性尿路感染症16例, 単純性膀胱炎1例に投与し, 以下の結果を得た。1) 複雑性尿路感染症のうち, 11例がUTI薬効評価基準に合致し, 著効2例, 有効4例, 無効5例で, 総合有効率54.5%であった。2) 細菌学的には, 14株中9株消失し, 64.3%の菌消失率であった。3) 投与量及び投与回数との関係では, 1回100mg, 1日2回投与で40%, 1回200mg, 1日1回投与で66.7%, 1回200mg, 1日2回投与で66.7%の有効率であった。4) 単純性膀胱炎症例は著効であった。5) 自他覚的副作用では胃部不快感と下痢が1例ずつみられた。また, 臨床検査値にて, GOT, GPT, ALPの上昇例を1例にみた。以上より, 本剤は複雑性尿路感染症を中心とした泌尿器科領域感染症に有用と考えられ, 特に1日1回投与法が良いと考えられた。
Fleroxacin, a novel new-quinolone, was administered to 17 patients and the results described below were obtained. 1. Of 11 patients with complicated urinary tract infection (UTI), excellent results were observed in 2, moderate in 4 and poor in 5. The overall clinical efficacy rate was 54.5%. 2. In bacteriological response, 9 of 14 strains (64.3%) were diminished. 3. As classified by dose and timing, clinical efficacy rates were 40% in the 100mg once daily group, 66.7% in the 200mg once daily group and 66.7% in the 200mg twice daily group. 4. Clinical efficacy in one case of acute uncomplicated cystitis was excellent. 5. Side effects were stomach discomfort and diarrhea in one case, and abnormal elevation of GOT, GPT and ALP in another.
Author MATSUMOTO, TETSURO
OGATA, NOBUO
KOIKAWA, YASUHIRO
KOMATSU, KIYOSHI
MIYAZAKI, NORIYOSHI
HARA, SANSHIN
KUMAZAWA, JOICHI
HIRATA, HIROSHI
TANAKA, MASATOSHI
Author_FL 田中 正利
鯉川 弥須宏
松本 哲朗
平田 弘
原 三信
尾形 信雄
熊澤 浮一
小松 潔
宮崎 徳義
Author_FL_xml – sequence: 1
  fullname: 松本 哲朗
– sequence: 2
  fullname: 田中 正利
– sequence: 3
  fullname: 尾形 信雄
– sequence: 4
  fullname: 熊澤 浮一
– sequence: 5
  fullname: 小松 潔
– sequence: 6
  fullname: 原 三信
– sequence: 7
  fullname: 宮崎 徳義
– sequence: 8
  fullname: 鯉川 弥須宏
– sequence: 9
  fullname: 平田 弘
Author_xml – sequence: 1
  fullname: MATSUMOTO, TETSURO
  organization: Department of Urology, Faculty of Medicine, Kyushu University
– sequence: 1
  fullname: HIRATA, HIROSHI
  organization: Department of Urology, Hiroshima Red Cross Hospital
– sequence: 1
  fullname: KOMATSU, KIYOSHI
  organization: Department of Urology, Sanshinkai Hara Hospital
– sequence: 1
  fullname: KOIKAWA, YASUHIRO
  organization: Department of Urology, Hiroshima Red Cross Hospital
– sequence: 1
  fullname: TANAKA, MASATOSHI
  organization: Department of Urology, Faculty of Medicine, Kyushu University
– sequence: 1
  fullname: KUMAZAWA, JOICHI
  organization: Department of Urology, Faculty of Medicine, Kyushu University
– sequence: 1
  fullname: OGATA, NOBUO
  organization: Department of Urology, Faculty of Medicine, Kyushu University
– sequence: 1
  fullname: HARA, SANSHIN
  organization: Department of Urology, Sanshinkai Hara Hospital
– sequence: 1
  fullname: MIYAZAKI, NORIYOSHI
  organization: Department of Urology, Hiroshima Red Cross Hospital
BackLink https://cir.nii.ac.jp/crid/1390001206285838080$$DView record in CiNii
BookMark eNpdkE9rwkAQxZfSQq31OxTaY2NndrLr7lFCtIFgwD_Q23YTdmtEY0jSg9--EXsQYXjDgzfD4_fE7qtj5Rh7RxgjcgEfxdYdjt3WNbY-oRY0JjVe_db13h1c1XEjSN-xASoVBkLp8J4NAEAHhFI8slHbljkAIkiu-IC9ztJ4mX1No2Tx0s9mmc3jRbKepr2bxdE6yRarZ_bg7b51o_89ZJtZvI4-gzSbJ9E0DXY8pC7gEw-555hLFBzRodD5JNTEc-0mLgTv0ReysCRJ6CL0QFqqQoLIvURAS0P2dvlblaUpyrMi6b488nNboUiBgj72fYnt2s7-OFM35cE2J2Obriz2ztzyMaTMNZ8b2-O6OrWNcRX9AVJPaeI
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1953.38.Supplement2_539
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate 泌尿器科領域感染症に対するFleroxacinの臨床的検討
DocumentTitle_FL 泌尿器科領域感染症に対するFleroxacinの臨床的検討
EISSN 1884-5894
EndPage 545
ExternalDocumentID 130004197169
article_chemotherapy1953_38_Supplement2_38_Supplement2_539_article_char_en
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
RJT
RZJ
ZOHVM
RYH
ID FETCH-LOGICAL-j243t-27f0bf21b615211e159b74932b9e7e40ff1fc6ca36359c4f03968c605bf6101a3
ISSN 0009-3165
IngestDate Thu Jun 26 23:41:52 EDT 2025
Wed Sep 03 06:09:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue Supplement2
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j243t-27f0bf21b615211e159b74932b9e7e40ff1fc6ca36359c4f03968c605bf6101a3
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1953/38/Supplement2/38_Supplement2_539/_article/-char/en
PageCount 7
ParticipantIDs nii_cinii_1390001206285838080
jstage_primary_article_chemotherapy1953_38_Supplement2_38_Supplement2_539_article_char_en
PublicationCentury 1900
PublicationDate 1990-00-00
PublicationDateYYYYMMDD 1990-01-01
PublicationDate_xml – year: 1990
  text: 1990-00-00
PublicationDecade 1990
PublicationTitle CHEMOTHERAPY
PublicationTitleAlternate Chemother.
PublicationTitle_FL ＣＨＥＭＯＴＨＥＲＡＰＹ
Chemother
PublicationYear 1990
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 2) AOYAMA H, INOUE M, MITSUHASHI S: In-vitro and in vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. J Antimicrob Chemother 22 (S-D): 99-114, 1988
1) HIRAI K, AOYAMA H, HOSAKA M, OOMORI Y, NIWATA Y, SUZUE S, IRIKURA T: In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother 29: 1059-1066, 1986
4) UTI研究会 (代表大越正秋): UTI薬効評価基準 (第3版). Chemotherapy 34: 408-441, 1986
3) NAKASHIMA M, KANAMARU M, UEMATSU T, TAKIGUCHI A, MIZUNO A, ITAYA T, KAWAHARA F, OOIE T, SAITO S, UCHIDA H, MASUZAWA K: Clinical pharmacokinetics and tolerance of fleroxacin in healthy male. volunteers. J Antimicrob Chemother 22 (S-D): 133-144, 1988
References_xml – reference: 2) AOYAMA H, INOUE M, MITSUHASHI S: In-vitro and in vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. J Antimicrob Chemother 22 (S-D): 99-114, 1988
– reference: 1) HIRAI K, AOYAMA H, HOSAKA M, OOMORI Y, NIWATA Y, SUZUE S, IRIKURA T: In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother 29: 1059-1066, 1986
– reference: 3) NAKASHIMA M, KANAMARU M, UEMATSU T, TAKIGUCHI A, MIZUNO A, ITAYA T, KAWAHARA F, OOIE T, SAITO S, UCHIDA H, MASUZAWA K: Clinical pharmacokinetics and tolerance of fleroxacin in healthy male. volunteers. J Antimicrob Chemother 22 (S-D): 133-144, 1988
– reference: 4) UTI研究会 (代表大越正秋): UTI薬効評価基準 (第3版). Chemotherapy 34: 408-441, 1986
SSID ssib001106282
ssj0000626693
ssib058492509
ssib005879733
ssib008506721
Score 1.2064006
Snippet Fleroxacin, a novel new-quinolone, was administered to 17 patients and the results described below were obtained. 1. Of 11 patients with complicated urinary...
Fleroxacin, a novel new-quinolone, was administered to 17 patients and the results described below were obtained.1. Of 11 patients with complicated urinary...
SourceID nii
jstage
SourceType Publisher
StartPage 539
SubjectTerms Fleroxacin
複雑性尿路感染症
Title FLEROXACIN IN UROGENITAL INFECTIONS
URI https://www.jstage.jst.go.jp/article/chemotherapy1953/38/Supplement2/38_Supplement2_539/_article/-char/en
https://cir.nii.ac.jp/crid/1390001206285838080
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX CHEMOTHERAPY, 1990/11/30, Vol.38(Supplement2), pp.539-545
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 19941231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: KQ8
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 20041231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: DIK
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfYkBAvCASIAZsqwVtISWLnw49ela5d1xi1iSi8RHbmSJ1EN03lYfvrOcepkw0kBlJk5dNyfJfz7xzf7xD66GFJY09PL9UyckkcElcIiV1MAlGRyBd-pOOd51k0KcjpKlx1y22b6JKtHFa3f4wr-R-pwjmQq46S_QfJ2krhBOyDfKEECUP5IBmPz9IFX7HRNHNgKxb8JM2mOTuDo3HarA5Z9sGnpj_g-SRdsC8WwM5ZDoaV59zJU9hbcOvKs4zNmDNnS5bz5cROrvITljMn48eFvXVWzNl39pU5p3w6au88byPrvM68w7Cs013ahaLNQhD1ow0Bu7ljPylYbZPdYaiMyUwS4oaJSVW8s6k46elOk5-0mewMeqYyNCRG7agbGlLJ3w06QDQQQ9Vrjv7xN8QJDC622tJWdoc6W_-q84ivWbLoHnocxABGNG6ezqzJ0YR9O4Y4M3gDYqE2_55-1yfo064lnx_QDoAyFwDsNWPD3ma97qGV_Dl61roZA2Z05gV6pDYv0YdOXwawdfoy6PTlFSrGaT6auG2SDPciIHjrBnHtyTrwZaSRmK8AnsqYACqXVMWKeHXt11VUCQzIklak9jCNkgqcWFkDcvYFfo32N5cb9QYNAgp4s4ppEMWCqFBnWjgX0qNKgdctVHyAvpk3K68ME0rZan55v1tKnJQ9qd8_hF7qPSqu4Vs-QIfQWWW11iV4Jc0MaRPfm2BNffr2L9ffoadap83k2Hu0v73-qQ4BLm7lUSPwXxk8XiA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FLEROXACIN+IN+UROGENITAL+INFECTIONS&rft.jtitle=CHEMOTHERAPY&rft.au=MATSUMOTO+TETSURO&rft.au=TANAKA+MASATOSHI&rft.au=OGATA+NOBUO&rft.au=KUMAZAWA+JOICHI&rft.date=1990&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=38&rft.issue=Supplement2&rft.spage=539&rft.epage=545&rft_id=info:doi/10.11250%2Fchemotherapy1953.38.supplement2_539&rft.externalDocID=130004197169
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon